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ABSTRACT 
 
Venom Peptide Induced Inhibition of Escherichia coli ATP synthase 
By  
Sofiya Azim  
 
 
 
ATP is the main cellular energy generated by the enzyme ATP synthase in almost all 
organisms from bacteria to vertebrates. While malfunction of the ATP synthase complex is 
responsible for several disease conditions, the enzyme itself can be used as a potent molecular 
drug target to combat many diseases including microbial infections, cancer, tuberculosis, and 
obesity. Recent widespread escalation of antibiotic resistant microbes in general and E. coli in 
particular demands novel alternative approaches to combat microbial infections. Inhibition of 
ATP synthase by inhibitors such as peptides is known to deprive microbes of required energy, 
resulting in microbial cell death. Therefore, we have examined the venom peptide induced 
inhibition of E. coli ATP synthase. It was found that venom peptides completely inhibited E. coli 
ATP synthase and the process of inhibition was found to be fully reversible. This study also links 
the antimicrobial properties of peptides in part to the inhibition of ATP synthase.  Thus, selective 
use of ATP synthase as a molecular drug may have an important impact on biology and 
medicine.  
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CHAPTER 1 
INTRODUCTION 
ATP synthase is the major source of energy production for all organisms from bacteria to 
vertebrates. Both the synthesis and hydrolysis of ATP occur on the catalytic sites of ATP 
synthase. This enzyme synthesizes ATP from ADP and Pi as well as hydrolyzes ATP depending 
on the physiological needs of the cell. ATP synthase works similarly to a motor and is actually 
the smallest known biological nanomotor found in living organisms. The clockwise rotation of 
ATP synthase generates ATP while hydrolysis of ATP occurs during counterclockwise rotation 
(1,2).   
  
 
 
 
 
 
 
 
 
 
ATP synthase (Figure 1) is a highly conserved enzyme among different species (3). In E. 
coli, ATP synthase has two sectors, F1 and Fo. The F1 sector has five different subunits, α3, β3, 
γ, δ, and ε. The Fo sector has three subunits, a, b2, and c10-14 (4). 
	  
Figure 1. Overall structure of ATP synthase 
modified from (3) 
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In total, ATP synthase has six nucleotide binding sites on its F1 sector. Three of them are 
noncatalytic while the other three are catalytic sites which are contributed by the α/β interface 
residues. ATP synthesis and hydrolysis takes place on the three catalytic sites. A proton gradient 
across the cell membrane moves protons through the Fo sector, which in turn rotates the γ-
subunit. Rotation of the γ-subunit causes the conformational changes in the α and β-subunits 
allowing them to bind or release nucleotide reactants (ATP, ADP, or Pi).  Functional 
significance of ATP synthase can be determined by the energy requirement of living organisms. 
For example, the total amount of ATP produced by a sedentary 70 kg human in about a 75 year 
life span is nearly 2 million kg. Such energy needs are fulfilled by the uninterrupted motor and 
catalytic function of ATP synthase (5).  
 
ATP synthase plays an exceptionally important role in human health and diseases. 
Malfunction of ATP synthase is known to result in life threating and debilitating diseases such 
as cancer, tuberculosis, obesity, neuropathies, Alzheimer’s, microbial infections, mitochondrial 
diseases, immune deficiency, cystic fibrosis, diabetes, ulcers, and Parkinson’s. The functional 
importance of ATP synthase also makes it a potential molecular target for anti-bacterial and 
anti-cancer drugs (6,7).  
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Figure 2.  Effect of ATP synthase inhibition on cell survival 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 2, the inhibition of ATP synthase can lead to cell death. When ATP 
synthase is functional, it can synthesize ATP from ADP and Pi. This will then allow the cell to 
grow because it has its required energy. In the event that ATP synthase is inhibited, the reaction 
between ADP and Pi does not occur and ATP is not generated. This will cause cell death 
because the cell will be deprived of its required energy (8). There are a variety of natural and 
synthetic compounds that are known to inhibit ATP synthase, including peptides, such that it 
has potential as a therapeutic drug target (8-10).  
 
Previously, ATP synthase inhibition has been used in a variety of beneficial ways. For 
example, Streptococcus mutans is a microbial agent that plays a major role in the pathogenesis 
of dental cavities by biofilm formation and acid production. Inhibition of S. mutans ATP 
synthase also inhibits biofilm formation and acid production, thus preventing the formation of 
cavities (11). It is the second largest killer after cancer. There are two mutations in the c-subunit 
 9 
of ATP synthase of the Mycobacterium which make the bacteria resistant to most tuberculosis 
drugs. These mutations, D32V and A63P can occur together or individually (12,13). In 2012, 
the FDA approved an anti-tuberculosis drug, Bedaquiline. It is extremely selective in its 
inhibition of the Fo sector of the ATP synthase in Mycobacterium tuberculosis. This drug 
eradicates the infection quickly and effectively (14).  ATP synthase inhibition also plays a role 
in angiogenesis. Angiogenesis is the process that involves the growth of new blood vessels from 
pre-existing vessels. This process is essential for tumor growth, and ATP synthase on the 
surface of endothelial cells is essential to angiogenesis in such cells. When non-mitochondrial 
endothelial cell surface ATP synthase is inhibited, formation of new vessels is prevented, 
thereby inhibiting tumor growth (15,16). 
 
Inhibition by peptides was first described in insects as an inducible system of protection 
against bacterial infections (17). Peptides are known to have powerful activity against bacteria, 
fungi, parasites, and viruses as well as selective anticancer activity (18,19). Currently, 
antimicrobial peptides (AMPs) are being used in several clinical trials with mixed success (8,20-
22). Widespread antibiotic-resistant microbial pathogens require new, alternative antimicrobial 
treatment choices (8,22). Some positively charged AMPs have been used against multidrug-
resistant microbes such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE), and multidrug resistant Pseudomonas aeruginosa (23-25). Cancer 
cells also exhibit numerous membrane protein targets including ectopic ATP synthases which 
peptide inhibitors could bind to as possible therapeutic molecules (6,26).   
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Figure 3 peptide binding βDELSEED-motif taken from reference (10) 
	  
  
 
 
 
 
 
 
 
Previously, it was found that melittin, melittin related peptide (MRP), and several 
structurally similar peptides inhibit the growth of E. coli cells by binding and inhibiting its ATP 
synthase. These cationic peptides were shown to bind at the βDELSEED-motif of ATP synthase 
(Fig. 3) (9,10).  
 
In this study we examined the two cationic venom peptide (VP1 and VP2) induced 
inhibitions of E. coli ATP synthase. Based on VP1 and VP2 induced inhibitory profiles of ATP 
synthase, we present direct evidence that ATP synthase is a potent molecular drug target for 
antimicrobial peptides. 
 
Hypothesis 
We hypothesized that venom peptides will inhibit the E. coli ATP synthase due to the fact 
that cationic peptides should bind at the peptide bind βDELSEED-motif of ATP synthase.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
Source of peptides: 
 Both venom peptides (VP1 and VP2) were purchased from Biomatik 
(http://www.biomatik.com).  The peptides were determined to have greater than 95% purity by 
HPLC. Lyophilized powder was stored at -20 oC upon receipt and resuspended in deionized 
water for use as needed.  
 
Chemicals: 
ATP disodium salt, glucose, uracil, TES, TRIZMA, 4-aminobenzamidine 
dihydrochloride (PAB), and Sodium dodecyl sulfate (SDS) were all purchased from Fisher 
Scientific or Sigma–Aldrich Chemical Company.  
 
Reagents:  
50 mM Tris-H2SO4 pH 8 (T8), Taussky and Shorr Reagent (T&S), 10% SDS, STEM, 
TES 50, and TES5 +PAB were prepared as described (10). 
 
Experimental Methods 
Preparation of membrane bound E. coli ATP synthase 
Grow wild-type E. coli in minimal media at 37oC and 250 rpm 
▼ 
Pellet at 9500 rpm for 15 min 
▼ 
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Resuspend pellet in STEM and spin at 9500 rpm for 25 min 
▼ 
Resuspend pellet in 2 ml Stem/g wet cells 
Add DNase and conduct Cell lysis by French press at 2000 psi 
▼ 
Spin at 22K rpm for 20 min 
▼ 
Spin supernatant at 60K rpm for 2 hours at 2oC 
▼ 
Resuspend pellet in TES 50 and spin at 60K rpm for 2hrs at 2oC 
▼ 
Resuspend pellet in TES 5 + PBA and spin at 60K rpm for 2 hours at 2oC 
(Repeat this step and store at - 70 oC 
 
The wild type E. coli strain used in this study was pBWU13.4/DK8 (27).  
 
Preparation of the membrane bound E. coli ATP synthase 
50 mL of minimal media was inoculated with a loop full of the wild type E. coli strain 
and was grown over night at 37 °C and 250 rpm. This 50 mL of overnight starter culture was 
inoculated into 1L of minimal media and was grown at 37 oC at 250 rpm. Growth was measured 
at OD595 on an hourly basis until the late log phase was obtained. 
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Once no further growth was seen, the cells were harvested by spinning them at 9500 rpm 
at 4 oC in a super speed centrifuge for 15 minutes. The harvested cells were then resuspended in 
STEM and once again centrifuged at 9500 rpm for 25 minutes. The supernatant was discarded 
and the pellet was resuspended in 2 mL of STEM/g of cells and was stored at -80 oC overnight 
until the next step. 
 
The stored cells were thawed and mixed with DNase to digest any nucleic acids. These 
cells were then disrupted by passing them through the French press at 2000 psi twice. Next, the 
lysed cells were centrifuged at 18K rpm for 20 minutes. Subsequently, the membrane bound E. 
coli ATP synthase was obtained by spinning the supernatant at 60K rpm for 120 minutes. The 
membrane bound E. coli ATP synthase was further resuspended in TES 50 and centrifuged at 
60K rpm for 120 minutes. This pellet was then washed with TES 5 + PAB by spinning it twice at 
60K rpm for 90 minutes. Finally, the purified membrane bound E. coli ATP synthase was 
resuspended in T8 buffer and stored at -80 oC for use in biochemical assays. 
 
Membrane Bound ATP Synthase Concentration and ATPase Assay 
Membrane bound E. coli ATP synthase concentrations were determined by plotting the 
absorbance at 595 nm using Bradford reagent against the standard BSA curve. ATPase activity 
was measured by adding 1 mL assay buffer containing 10 mM NaATP, 4 mM MgCl2, and 50 
mM TrisSO4 (pH 8) to 20 µg of membrane bound E. coli ATP synthase at 37 °C. The reaction 
was stopped with SDS. The released Pi (inorganic phosphate) was measured by adding 1 mL of 
T&S reagent and was read at OD700.  
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The enzymatic reaction of ATP synthase is as follows: ATP + ATP synthase ⇌ ADP + Pi 
and Pi + T & S → blue color. The intensity of the blue color observed at 700 nm is directly 
proportional to the activity of the enzyme. 
 
Activity of ATP synthase was calculated by using the following formula 
Average of Sample OD - Average of Blank OD = …………….. µmol/min/g protein        
  Amount of protein (mg) x Time (min) 
 
Inhibition of E. coli ATP synthase by venom peptides, VP1 and VP2 
Wild-type membrane bound F1Fo ATP synthase was preincubated with different 
concentrations of VP1 and VP2 for 60 minutes at room temperature (RT) in 50 mM TrisSO4 at 
pH 8.0.  1 mL of ATPase cocktail was used to measure the enzyme activity. The reaction was 
stopped by the addition of 1 mL of SDS to a final concentration of 3.3%. 1 mL of T&S reagent 
was added to develop the blue color and was assayed at OD700 (28). Inhibitory exponential decay 
curves were generated with Sigma plot 10.0. The range of absolute specific activity for 
membrane bound F1Fo ATP synthase was 15–20 µmol/min/mg at 37 oC for different 
preparations.  Relative ATPase activity was calculated from the absolute values of wild type in 
the absence of peptides taken as 100%. 
 
Reversal of peptide inhibited ATPase activity  
 Reversibility of inhibition was checked by dilution of the membrane bound enzyme. 
Membrane bound ATP synthase was first reacted with the maximal inhibitory concentration of 
peptides for 1 hour. Next, T8 buffer was used to bring the venom peptide concentrations to non-
inhibitory levels and they were then incubated for one additional hour before measuring the 
ATPase activity.   
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Figure 4. Venom peptides (VP1 and VP2) induced inhibition of ATP synthase. 
CHAPTER 3 
RESULTS 
Venom peptide induced inhibition of E. coli ATP synthase 
Figure 4 shows the inhibition of membrane bound E. coli ATP synthase in the presence 
of varied concentrations of venom peptides (VP1 and VP2). While VP1 caused approximately 
70% inhibition with 30% residual activity, VP2 completely inhibited ATP synthase with 
essentially no residual activity (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Reversal of ATPase activity of membrane ATP synthase from the venom peptide inhibition  
To test for the reversibility of venom peptide induced inhibition, membrane bound ATP 
synthase was treated with the maximum inhibitory concentrations of venom peptides for 1 hour 
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at 37 oC as shown in Figure 4. Then, the samples were diluted to non-inhibitory concentrations 
by adding T8 buffer, and ATPase activity was measured at OD700. Inhibition by both venom 
peptides (VP1 and VP2) was found to be reversible (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 5 Reversal of VP1 and VP2 induced inhibition of 
membrane bound E. coli ATP synthase enzyme. 
(Enzyme:Enz ; Dilution:Dil)  
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CHAPTER 4 
DISCUSSION 
The purpose of this study was to examine whether or not the antimicrobial properties of 
peptides in general and venom peptides in particular, may be linked to the inhibition of ATP 
synthase. The results of this study demonstrate that both the studied venom peptides, VP1 and 
VP2, do bind and inhibit bacterial ATP synthase.  VP2 was found to be a more potent inhibitor 
causing nearly 100% inhibition while VP1 caused about 70% inhibition. Previously, a number of 
α-helical cationic peptides were shown to inhibit ATP synthase (9).  These include melittin, a 
26- residue long honeybee venom peptide, the bacterial/chloroplast ε subunit, and several AMPs 
from amphibian origin that are the most important α-helical peptide inhibitors of ATP synthase 
(6,9,29-33).  
 
Peptides bind at the β-subunit residues 380-386 of the βDELSEED- motif as shown in 
Figure 3.  It has been demonstrated that the positively charged peptide residues exert their 
inhibitory effect through electrostatic interactions with the negatively charged βDELSEED-motif 
of ATP synthase (34). Similarly, it seems that that the direct electrostatic interactions between 
the venom peptides and acidic residues of the βDELSEED-motif are responsible for the 
inhibition of membrane bound E. coli ATP synthase.  
 
The presence of 15 positively charged residues clustered in groups in a 34-residue long 
VP1 venom peptide may be the reason for partial inhibition of ATP synthase. Too many positive 
charges may cause steric hindrance for proper binding and inhibition of ATP synthase. Potent 
inhibition by venom peptide VP2 may be attributed to its 12 positively charged residues spread 
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widely in a 30-residue long peptide. It can be concluded that such dispersion not only decreases 
the repulsion among positively charged residues, but also helps in the proper orientation of the 
peptide for tighter binding and inhibition.   
 
The process of inhibition was also found to be fully reversible. Membrane bound ATP 
synthase regained activity once it was brought back to non-inhibitory venom peptide 
concentrations by dilution with T8 buffer (Figure 5). This reversible process of inhibition 
indicates a non-covalent binding of venom peptides VP1 and VP2 at the βDELSEED-motif of 
wild-type E. coli ATP synthase (9).  
 
 Peptides are known to have pharmacological uses as antimicrobial (35,36) and anticancer 
agents (37). Many mechanisms have been postulated for their mode of action including 
membrane penetration (38,39) and cytolytic membrane disintegration (40). Most peptides are 
known to affect gram-negative and gram-positive bacteria, fungi, viruses, eukaryotic parasites, 
and cancer cells (37,41). Programmed cell death through the mitochondrial pathway inhibiting 
ATP synthase as a molecular target by several natural and synthetic inhibitors has been 
previously established (42-45).  Additive effects of different α-helical AMPs have also been 
observed (46). These observations suggest that the combined effects of two or more inhibitors, or 
functional group modulation of inhibitors, may increase the extent and potency of inhibition.  
 
 Lately, the role of ATP synthase in the pathophysiology of many human disease 
conditions has become clearer (8).  Due to this, the identification and characterization of potent 
inhibitors of ATP synthase on molar scale is extremely important. We conclude that further 
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identification and characterization of venom peptides is a promising avenue for understanding 
ATP synthase as a potential drug target for peptides.  
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